Cardiol Therapeutics
CRDL
43 hedge funds and large institutions have $9.6M invested in Cardiol Therapeutics in 2024 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 11 closing their positions.
3,660% more call options, than puts
Call options by funds: $188K | Put options by funds: $5K
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
5% more funds holding
Funds holding: 41 → 43 (+2)
2.07% more ownership
Funds ownership: 7.12% → 9.18% (+2.1%)
3% less capital invested
Capital invested by funds: $9.85M → $9.6M (-$253K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
Tejara Capital
London,
United Kingdom
|
+$2.27M |
| 2 |
PAM
PVG Asset Management
Golden,
Colorado
|
+$822K |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$522K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$454K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$391K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$486K |
| 2 |
FIA
Foundations Investment Advisors
Phoenix,
Arizona
|
-$321K |
| 3 |
UBS AM
Chicago,
Illinois
|
-$109K |
| 4 |
Two Sigma Investments
New York
|
-$48.8K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$33.5K |
CRDL Hedge Fund Activity: Q4 2024 in Review
43 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Cardiol Therapeutics (CRDL) for Q4 2024, worth a combined $9.6M — down 2.6% from $9.85M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CRDL positions and 11 closed out — a net gain of 2 holders — while 11 added to existing stakes and 6 trimmed.
The largest buyer was Tejara Capital, adding an estimated $2.27M. The largest seller was AdvisorShares Investments, cutting an estimated $486K.
- 43 institutional investors held Cardiol Therapeutics (CRDL) as of Q4 2024, up from 41 in Q3 2024.
- Funds reported $9.6M of Cardiol Therapeutics stock for Q4 2024, down 2.6% quarter-over-quarter.
- 13 funds opened new Cardiol Therapeutics positions in Q4 2024 and 11 closed out, a net change of +2 holders.
- The largest Cardiol Therapeutics buyer in Q4 2024 was Tejara Capital, an estimated $2.27M added.
- The largest Cardiol Therapeutics seller in Q4 2024 was AdvisorShares Investments, an estimated $486K sold.
Based on aggregated 13F filings for Q4 2024.